Primozida [INN-Spanish]
Brand names,
Primozida [INN-Spanish]
Analogs
Primozida [INN-Spanish]
Brand Names Mixture
Primozida [INN-Spanish]
Chemical_Formula
C28H29F2N3O
Primozida [INN-Spanish]
RX_link
http://www.rxlist.com/cgi/generic3/orap.htm
Primozida [INN-Spanish]
fda sheet
Primozida [INN-Spanish]
msds (material safety sheet)
Primozida [INN-Spanish]
Synthesis Reference
No information avaliable
Primozida [INN-Spanish]
Molecular Weight
461.546 g/mol
Primozida [INN-Spanish]
Melting Point
214-218 oC
Primozida [INN-Spanish]
H2O Solubility
10 mg/L
Primozida [INN-Spanish]
State
Solid
Primozida [INN-Spanish]
LogP
5.761
Primozida [INN-Spanish]
Dosage Forms
Tablet
Primozida [INN-Spanish]
Indication
Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
Primozida [INN-Spanish]
Pharmacology
Pimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).
Primozida [INN-Spanish]
Absorption
Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.
Primozida [INN-Spanish]
side effects and Toxicity
LD50 = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)
Primozida [INN-Spanish]
Patient Information
No information avaliable
Primozida [INN-Spanish]
Organisms Affected
Humans and other mammals